News
Novartis, through its Alcon eye-care division, intends to start clinical trials of an accommodative Google “smart” contact lens in human eyes next year, Novartis Chief…
Read More
Last week’s sale of Aquesys represented a homecoming for CEO Ron Bache, who started his surgical device career at Allergan in the late 1990s. However,…
Read MoreCan Accommodating IOLs Fuel Demand? For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of…
Read MoreAs a rule, medical device companies have to demonstrate some level of commercial viability if they’re going to go public. A few are able to…
Read MoreThere’s more to the 21st Century Cures Act, which passed the full House of Representatives with overwhelming bipartisan support, than $9 billion in new funding…
Read MoreWhile our podcast this week examines the rise of Glaukos and the MIGs market, contributor Michelle Dalton presents a State of the Glaucoma Drugs address.…
Read More
Shire this week announced plans to acquire Foresight Biotherapeutics for $300 million. Robert Dempsey, Shire’s vice president and head of the company’s ophthalmic unit, kindly…
Read MoreWith three of the four sustained-release drug delivery products commercially available in the U.S. and Europe, pSivida just might prove Wall Street pundits correct and…
Read More
The first biosimilar agent for Lucentis (ranibizumab, Genentech) has come to market in India with the launch of Intas Pharmaceuticals’’ Razumab in June. But whether…
Read MoreMedtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary…
Read More
The dry eye space has taken a few hits lately with disappointing clinical news on the biopharmaceutical front. But investors and entrepreneurs developing new treatments…
Read MoreOIS Hot Shot Glaukos Corp. (NASDAQ—GKOS) raised over $100 million in an initial public offering (IPO) that highlighted extraordinary demand for ophthalmology’s minimally invasive glaucoma…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")